ClinicalTrials.gg
CompletedNCT07860736Updated Oct 6, 2026

A Food Effect Study of Pitolisant Delayed-Release in Healthy Adult Participants

A Phase 1 interventional study of Pitolisant delayed-release in Healthy Participants, sponsored by Harmony Biosciences Management, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open label, randomized, 2-way crossover study to assess the effect of a low-fat meal on the pharmacokinetics of pitolisant delayed-release in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Food Effect Study
03

In context

Lead sponsor

Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is able to provide voluntary, written .
  • Continuous nonsmoker who has not used nicotine- or tobacco-containing products for at least 3 months prior to the first dosing.

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or expected during the conduct of the study.
  • History or presence of medical or psychiatric condition or disease, including depression, bipolar disease, or psychosis, in the opinion of the PI or designee.
  • Has acute or chronic liver disease or a history of moderate hepatic impairment ( Class B) or severe hepatic impairment (Child-Pugh Class C).

Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Pitolisant Delayed-release: Fasted then Fed

    Participants will receive 35.6 milligrams (mg) pitolisant delayed-release under fasted conditions. After a washout period of at least 10 days, participants will then receive 35.6 mg pitolisant delayed-release following a low-fat meal.

    Drug: Pitolisant delayed-release

  • Experimental
    Pitolisant Delayed-release: Fed then Fasted

    Participants will receive 35.6 mg pitolisant delayed-release following a low-fat meal. After a washout period of at least 10 days participants will then receive 35.6 mg pitolisant delayed-release under fasted conditions.

    Drug: Pitolisant delayed-release

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under The Concentration-time Curve, From Time 0 To The Last Observed Non Zero Concentration (AUClast)

    Time frame: Pre dose and up to 72 hours post dose

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events

    Time frame: Up to 3.5 weeks

07

Study locations

1 site
  • Celerion Inc
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Jun 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Jun 18, 2026
Primary completionActual
Jun 28, 2026
CompletionActual
Jul 12, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860736
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Jun 18, 2026
Primary completion
Jun 28, 2026
Completion
Jul 12, 2026
Last update
Oct 6, 2026

Study contacts

Robert Faulkner, PhD
study director · Harmony Biosciences Management, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBS-301

Start the discussion